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Background: Meningiomas are the most common adult primary intracranial tumors in
the United States. Despite high recurrence rate of atypical and malignant subtypes,
there is no approved drug indicated specifically for meningioma. Since the majority of
meningiomas exhibit high density of somatostatin receptors subtypes, somatostatin
analogs have been under close investigation. The aim of this study was to evaluate
efficacy and safety of Sandostatin LAR (octreotide) in patients with progressive, and/or
recurrent meningioma, and identify subset of patients who were more likely to benefit
from this treatment.
Methods: A total of 43 patients ≥ 18 years old were included in the retrospective
chart review. The patients underwent treatment with Sandostatin LAR (octreotide)
from 01.01.2010 to 06.01.2017 at the University of California, Irvine after confirmation
of the diagnosis. Six months progression free survival (PFS6) was defined as a
primary endpoint, and the overall survival (OS), safety, and toxicity were identified as
secondary endpoints.
Results: The OS for 6 months, 1, and 3 years for all WHO grades was
94.8, 88.1, and 67.0%, respectively. The PFS6 for WHO I, II, III, and all was
89.4, 89, 33.3, and 80% respectively. For patients with no prior surgeries,
chemotherapy or radiation, the PFS6 was 88.9, 84.8, and 94.8%, respectively.
Interestingly, the PFS6 was 90.5% for skull-based and 80% for 3–6 cm tumors.
Patients with tumors in parasagittal location had PFS6 of 83.3% compared to
PFS6 of 50.0% for patients with convexity tumors. Evaluation of PFS6 based on
the effect of estrogen and progesterone on meningioma identified that ER-PR+
tumors had PFS6 of 87.8% while patients with ER-PR- meningiomas had PFS6
of 62.5%. Median TTP for WHO grade I, II, and III was 3.1, 2.40, and
0.26 years, respectively. Subgroup analysis showed that median TTP was 3.1
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years for < 3 cm tumors, 3.22 years for skull-based tumors, 2.37 years for patients with
prior surgeries and 3.10 years for patients with no history of chemotherapy. History of
radiation had no effect on median TTP. Sandostatin LAR (octreotide) was well-tolerated.
Conclusions: This is one of the largest retrospective analysis of meningioma patients
treated with Sandostatin LAR (octreotide) suggesting that this treatment has minimal
to no adverse events and could prolong overall survival, and progression free survival
especially for patients with ER-PR+ tumors who underwent surgeries for small
skull-based tumors.
Keywords: recurrent progressive meningioma, Somatostatin LAR, octreotide, skull based meningioma,
meningioma size, meningioma surgery
INTRODUCTION
For Meningiomas are dural-based tumors that arise from an
arachnoid layer or meningothelial cells. They are the most
common primary adult CNS tumors, and account for 36.8% of all
primary brain tumors (1). Most meningiomas are histologically
classified as World Health Organization (WHO) grade I tumors
(benign, 81.3%) with an indolent course.WHO grade II (atypical,
16.9%) and WHO grade III (anaplastic, 1.7%) tumors classified
as high-grade tumors and known to be more aggressive with
increased risk of recurrence (2).
If indicated based on tumor size or tumor progression,
patients with WHO grade I meningiomas undergo complete
surgical resection (3). Approximately 5% of completely
resected benign meningiomas, 30% of partially resected benign
meningiomas and 40% of atypical meningiomas recur within 5
years after surgery (4). Despite surgical resection and radiation
therapy that is the standard of care for WHO grade II and
III meningiomas, patients have higher recurrence risk of
29–52 and 50–94%, respectively (5). Depending on tumor
location, invasion of surrounding structures, age, and medical
comorbidities of the patient, surgical intervention is not always
possible. Chemotherapy or biologics are then considered as an
alternate treatment option. There is no FDA approved drug
indicated specifically for meningioma, and patients with atypical,
anaplastic, recurrent, or invasive meningiomas are often left with
limited options.
The National Comprehensive Cancer Network (NCCN)
guideline identified three drug classes that showed some
benefits for treatment of meningioma in retrospective analysis
or small phase II trials: vascular endothelial growth factor
(VEGF) signaling pathway inhibitors, alpha-interferons, and
somatostatin receptor agonists (6, 7). Since the majority of
meningiomas exhibit a high density (70%) of somatostatin
receptors subtypes (SSTR1–SSTR5), it is not surprising that
somatostatin analogs have been under close investigation as a
potential treatment option (8, 9).
Somatostatin is an acyclic tetradecapeptide hormone that
is produced in hypothalamus and released into systemic
circulation, where it exhibits its exocrine and endocrine
inhibitory functions by targeting pituitary, pancreas and
gastrointestinal tract (10). It also has been implicated in the
induction of apoptosis and inhibition of angiogenesis (11).
Since naturally occurring somatostatin has a short half-life,
somatostatin analogs were developed to achieve a longer half-life
(lanreotide, pasireotide, and octreotide).
Sandostatin LAR (octreotide) is another long acting
somatostatin analog approved by the FDA for treatment of
acromegaly, severe diarrhea/flashing episodes associated with
metastatic carcinoid tumors, and vasoactive intestinal peptide
(VIP) secreting tumors (12).
Numerous in vitro studies investigated antitumor effect of
octreotide acetate. For instance, Arena et al. evaluated a role of
SSTR in the control of human meningioma cell proliferation
and identified that in four out of six primary cell cultures
obtained from fresh meningioma surgical sample, the treatment
with somatostatin caused inhibition of DNA synthesis induced
by the tumor-promoter phorbol myristate acetate (13). Graillon
et al. investigated the signal transduction pathways triggered by
octreotide and correlated inhibition to cellular markers using a
large set of all histological subtypes of meningioma (14). Study
showed that octreotide significantly decreased cell proliferation
in 88% of meningiomas but did not induce cell death. It was
postulated that it had an effect on the level of phosphorylated
p70-S6 kinase implicated in rapamycin (mTOR) pathway.
Given that Sandostatin LAR (octreotide) was shown to
significantly decrease cell proliferation in 88% of meningiomas
with more prominent inhibition in a group expressing a high
level of SSTR2a, one of the most frequently expressed receptors
in meningiomas, investigative work was initiated to assess its
efficacy for treatment of meningiomas (8, 15).
A prospective pilot study showed that 31% of patients with
recurrent meningiomas demonstrated a partial radiographic
response and 44% achieved progression free survival (PFS) at 6
months with minimal side effects after undergoing treatments
with Sandostatin LAR (octreotide) (16). Even though a phase
II study conducted to evaluate the efficacy and safety of
Sandostatin LAR (octreotide) did not demonstrate a significant
benefit, 2 patients experienced prolonged stability of previously
progressive tumors (17). Studies that investigated the effect of
Sandostatin LAR (octreotide) in patients with a progressive
benign residual or recurrent meningioma of the skull base,
showed that somatostatin analog can arrest progression and
stabilized disease (14).
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Numerous clinical studies highlighted potential benefit of
Sandostatin LAR (octreotide) for treatment of meningioma, but
due to small sample size, no statistical significance was achieved.
Thus, our retrospective interventional cohort study with a bigger
sample size provides supporting evidence to consider Sandostatin
LAR (octreotide) as a potential candidate for meningioma-based
treatment taken into an account its tolerability and safety profile.
MATERIALS AND METHODS
The following study was a retrospective interventional cohort
analysis conducted at the University of CaliforniaMedical Center
(UCIMC) between January 2010 and June 2017. The study cohort
consisted of patients with recurrent and/or progressive WHO
grade I, II, or III meningiomas who received treatment with
Sandostatin LAR (octreotide). All information related to patients’
demographics, cancer type, response to treatment, therapies
previously received, and Karnofsky performance scores (KPS)
were collected (18). The primary objective of this study was to
determine efficacy of Sandostatin LAR (octreotide) in patients
with recurrent and/or progressive meningiomas. Six months
PFS6 was defined as a primary endpoint, and OS was a secondary
endpoint. Safety and toxicity of Sandostatin LAR (octreotide)
were assessed as well (19).
Patients Eligibility
Patients were required to be ≥ 18 years old with recurrent
and/or progressive meningioma expressing sandostatin
receptors confirmed by positive 111Indium (111In)—octreotide
positron emission tomography (PET) and/or positive
immunohistochemistry analysis. The majority of the patients
(38) had positive PET scan while remaining patients (5) were
diagnosed based on the pathology results. Histological typing and
grading of tumors according to the WHO grading system were
done via hematoxin and eosin staining. Immunohistochemical
staining were done for estrogen receptor (ER), progesterone
receptor (PR), Ki-67 and Sandostatin based on the University
of California of Irvine protocol. Patients were determined to be
poor candidates for surgical resection, stereotactic radiosurgery,
or radiation therapy based on tumor location, increased risk
factors for postoperative morbidity and mortality, or individual
preference for non-invasive approach, or were shown to have
recurrence despite surgical or radiation therapy. Patients who
suffered from meningioma recurrence were offered treatment
independent of history of prior surgeries, chemotherapy,
radiation, or radiosurgery treatments. Patients were excluded
if metastatic lesions were found on octreotide PET scan or
informed consent was not obtained.
Tumor Variables
Tumor size and location were obtained from the MRI scan and
official radiologist’s report. The largest diameter was used as an
overall surrogate for tumor size. Tumor size was categorized
into 3 groups: small (tumor <3.0 cm in diameter), medium
(tumor ranging 3–6 cm in diameter) and large (tumor more
than 6 cm in diameter). Tumor location was subdivided into
3 groups: skull based (cavernous sinus, cerebellopontine angle,
clinoid, clivus, foramen magnum, jugular foramen, middle fossa,
olfactory groove, orbital, parasellar, petro-clival, petrous, planum
sphenoidale, posterior fossa, skull base, sphenoid wing, and
tuberculum sellae), falx/parasagittal/convexity, and mixed.
Treatment Plan
The diagnosis of meningioma was confirmed either via 111In-
octreotide PET scan or by immunohistochemical analysis.
Imaging study (MRI or CT) was done prior to the first drug
administration and was repeated every 2–3 months afterwards
for an evaluation of tumor status. Imaging studies were used to
define the disease recurrence. Patients received deep intragluteal
injections of Sandostatin LAR (octreotide) monthly and were
treated until disease progression or intolerability. The dose of
Sandostatin LAR (octreotide) was gradually increased from 30 to
40mg per injection if tolerated. Patients were followed for any
adverse reactions to the drug. The treatment was stopped if the
patient met any of the following criteria: MRI or CT showed
tumor progression, serious adverse events, physician discretion,
patient’s choice to discontinue treatment, death, or lost to follow
up. The institutional review board approved the study, and all
patients that participated provided written informed consent.
Statistical Methods
Data was analyzed using the IBM SPSS statistical program
package (PAWS statistics v18.0). Data was grouped into
categories based on demographics, WHO tumor grades, KPS
scores, tumor and treatment characteristics, and analyzed using
descriptive statistics. The PFS was calculated from the date of
initial treatment with Sandostatin LAR (octreotide) until the date
of death or disease progression. Patients who did not experience
disease progression were censored. The OS was estimated from
the date of initial treatment with Sandostatin LAR (octreotide) to
the date of death or last known date to be alive. Subjects that have
not died were censored at the last known date to be alive. Survival
curves were estimated by generating Kaplan-Meier methods. PFS
and OS were compared betweenWHO tumor grades, tumor, and
treatment characteristics. The log rank test was used to compare
the survival distributions of the groups. P < 0.05 for all analyses
was considered significant. A proportional-hazards model was
used to delineate the risk of death adjusted for covariates.
Best radiographic response was determined based on 2010 the
Response Assessment in Neuro-Oncology (RANO) Working
Group (20). Results from our treatment group were compared to
results from previous published studies using Sandostatin LAR
(octreotide) for treatment of meningioma.
Safety and Toxicity
Adverse events were reported by patients and/or providers
when abnormal laboratory or physical examination findings
were identified requiring intervention. Adverse events were
recorded from the first date of Sandostatin LAR (octreotide)
administration until death or 12 months follow up. The
relationship of the adverse event to Sandostatin LAR (octreotide)
was also evaluated. It was considered to be a related event when
there was an evidence to suggest the relationship between the
drug and the adverse event. An unrelated event was thought to
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be an adverse event, possibly caused by an underlying disease or
biologically improbable event. Safety results were evaluated via
descriptive statistics to identify frequency, type, and severity of
adverse events.
Treatment related toxicities were evaluated using the
Common Terminology Criteria for Adverse Events (CTCAE)
version 4.03 (21). All patients who received Sandostatin LAR
(octreotide) were evaluable for toxicity, and toxicity results were
compared to other clinical studies.
RESULTS
Patients Characteristics
A total of 43 patients with recurrent or progressive WHO grade I
(75.0%), II (11.4%), and III (13.6%) meningiomas were enrolled
in this study, including 5 with atypical and 6 with anaplastic
meningiomas (Table 1). The majority of patients were females
(70.5%) who identified as White (38.6%), Hispanic (25.0%),
or Asian (22.7%). Median age was 65 years old. Median KPS
score was 80. Median number of Sandostatin LAR (octreotide)
injections was 8. Evaluation of prior treatments identified
that 75.0% of patients with all tumor grades had surgical
resections, 45.4% had radiation therapy while 13.6% underwent
chemotherapy. Analysis of prior recurrences identified 12
patients withWHOgrade I tumors who had no prior recurrences,
7 patients with one recurrence, 10 patients with two recurrences,
and 4 patients with three or more recurrences. All patients with
WHO grade II and III meningiomas were noted to have two or
more recurrences. The cohort consisted of small (<3.0 cm) and
medium (3–6 cm) tumors that were predominantly skull base
tumors (23 patients). We identified 25 patients with ER positive
(ER+), one patient with ER negative (ER-), 18 patients with PR
positive (PR+), and 8 patients with PR negative (PR-) statuses.
Subgroup analysis showed 17 patients with ER+PR+, 8 patients
with ER-PR- and one patient with ER-PR- statuses.
Toxicity
Toxicity data is reported for all 43 patients (Table 2). In
general, therapy with Sandostatin LAR (octreotide) was well-
tolerated. No CTCAE grade 4 or 5 adverse events were observed.
Sandostatin LAR (octreotide) treatments were discontinued in
two patients after they experienced significant adverse events.
One patient developed cholelitiasis complicated by pancreatitis
identified as grade 3 adverse event. The other patient experienced
vomiting that was defined as grade 2 event. The majority of
grade 2 adverse events included diarrhea (11.4%), headache
(6.8%), nausea (4.5%), and abdominal pain (4.5%). Patients more
frequently experienced grade 1 events with diarrhea (27.3%) and
headache (27.3%) being most common side effects.
Response and Outcome
Analysis indicated that the median PFS for all tumor grades
was 3.0 years (95% CI: 2.20–3.80), PFS6 80.6% (95% CI: 0.68–
0.93), PFS12 71.9% (95% CI: 0.58–0.86), and PSF36 46.2% (95%
CI: 0.21–0.72) (Table 3.1). The median PFS for WHO grade I
meningiomas was 3.1 years (95% CI: 2.80–3.40), PFS6 89.8%
(95% CI: 0.79–1.00), PFS12 82.0% (95% CI: 0.67–0.97), and
TABLE 1 | Patient demographic and clinical characteristics (n = 43).
Characteristics All Patients
Median Age
(years) (range)
66 (35–90)
Male, No. (%) 13 (29.5)
Female, No. (%) 30(70.5)
Ethnicity/race, no. (%)
• White
• Hispanic
• Asian
• Other
16 (37.2)
11 (25.6)
9 (20.9)
7 (16.3)
Median number of
Sandostatin LAR
injections
8 treatments (1–25)
KPS score at baseline, no. (%)
• 50
• 60
• 70
• 80
• 90
• 100
• Median
1 (2.3)
2 (4.5)
9 (20.5)
15 (34.1)
13 (29.5)
3 (7)
80
WHO tumor grade no. (%)
• 1
• 2
• 3
32 (74.4)
5 (11.6)
6 (13.9)
WHO
Grade 1
WHO
Grade 2
WHO
Grade 3
All Grades
Prior treatments no. (%)
• Resection
• Chemotherapy
• Radiation therapy
24 (55.8)
3 (7.0)
12 (30.0)
5 (11.6)
1 (2.3)
2 (4.7)
5 (11.6)
3 (7.0)
6 (14.0)
34 (79.1)
7 (16.3)
20 (46.5)
Previous recurrences no. (%)
• 0
• 1
• 2
• 3 <
11 (25.6)
7 (16.9)
10 (23.3)
4 (9.3)
0 (0)
0 (0)
3(7.0)
2 (4.7)
0 (0)
0 (0)
2 (4.7)
4 (9.3)
11 (25.6)
7 (16.9)
15 (34.8)
10 (23.3)
Tumor size no. (%)
• Small (< 3.0 cm)
• Medium
(3–6 cm)
• Large (> 6 cm)
17 (39.5)
14 (32.6)
1 (2.3)
1 (2.3)
3 (7.0)
1 (2.3)
2 (4.7)
4 (9.3)
0
20 (46.5)
21 (51.2)
2 (4.7)
Tumor location no. (%)
• Skull base
• Parasagittal
• Convexity/Falx
• Mixed
21 (48.8)
3 (7)
3 (7)
5 (11.6)
1 (2.3)
1 (2.3)
3 (7)
0
1(2.3)
2 (4.7)
3 (7)
0
23 (53.5)
6 (34.8)
9 (20.9)
5 (11.6)
PSF36 61.5% (95% CI: 0.25–0.98). The median PFS for WHO
grade II meningiomas was 2.4 years (95% CI: 1.40–3.30), PFS6
80.0% (95% CI: 0.45–1.00), PFS12 80.0% (95% CI: 0.45–1.00),
and PSF36 30.00% (95% CI: 0.00–0.77). The median PFS for
WHO grade III meningiomas was 0.2 years (95% CI: 0.05–0.36),
patients in this group did not survive past 6 months. The log
rank test had a value of p < 0.001 which means that there was
a statistically significant difference in PFS between the WHO
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TABLE 2 | Treatment related CTCAE adverse events (n = 43).
Adverse events CTCAE Grade 1
No. (%)
CTCAE Grade 2
No. (%)
CTCAE Grade 3
No. (%)
CTCAE Grade 4
No. (%)
CTCAE Grade 5
No. (%)
Total No. (%)
Diarrhea 12 (28) 4 (9.3) 0 0 0 16 (37.2)
Loose stools 5 (11.6) 0 0 0 0 5 (11.6)
Headache 11 (25.6) 3 (7.0) 0 0 0 14 (32.6)
Local pain 6 (14.0) 0 0 0 0 6 (14.0)
Flu like symptoms 3 (7.0) 1 (2.3) 0 0 0 4 (9.3)
Weakness 1 (2.3) 1 (2.3) 0 0 0 2 (4.7)
Palmar redness 1 (2.3) 0 0 0 0 1 (2.3)
Chills 1 (2.3) 0 0 0 0 1 (2.3)
Sweats 1 (2.3) 0 0 0 0 1 (2.3)
Arthralgia 1 (2.3) 0 0 0 0 1 (2.3)
Nausea/vomiting 3 (7.0) 2 (4.7) 0 0 0 5 (11.6)
Abdominal pain 2 (4.7) 2 (4.7) 0 0 0 4 (9.3)
Insomnia 3 (7.0) 1 (2.3) 0 0 0 4 (9.3)
Dizziness 4 (9.3) 0 0 0 0 4 (9.3)
Constipation 9 (20.9) 1 (2.3) 0 0 0 10 (23.3)
Anxiety 0 (0) 1 (2.3) 0 0 0 1 (2.3)
Fatigue 4 (9.3) 0 0 0 0 4 (9.3)
Pancreatitis 0 0 1 (2.3) 0 0 1 (2.3)
Cholelithiasis 0 0 1 (2.3) 0 0 1 (2.3)
Abdominal bloating 1 (2.3) 0 0 0 0 1 (2.3)
TABLE 3.1 | Median progression free survival and progression free survival at 6 months, 1 year, and 3 years (n = 43).
PFS WHO Grade 1
(CI 95%)
WHO Grade 2
(CI 95%)
WHO Grade
3 (CI 95%)
ALL (CI 95%)
6 months 89.4% (0.78–1.00) 80.0% (0.45–1.00) 33.3% (0.00–0.71) 80% (0.67–0.92)
1 year 81.5% (0.67–0.96) 80.0% (0.45–1.00) – 68.3% (0.53–0.83)
3 years 61.1% (0.25–0.97) 30.0% (0.00–0.77) – 45.9% (0.20–0.71)
Median PFS
Median 3.1 years 2.4 years 0.2614 years 2.97 years
(3.0–4.5) (1.3–3.2) (0.17–1.0) (1.76–4.53)
(–), undetermined.
FIGURE 1 | (A) Kaplan–Meier plot demonstrating overall survival by WHO tumor grades and polled across WHO grades. (B) Kaplan–Meier plot demonstrating
progression free survival by WHO tumor grades and polled across WHO grades. (C) Kaplan–Meier plot demonstrating progression free survival by tumor location and
polled across locations.
tumor grade groups. Kaplan-Meier curves were generated to
analyze the overall PFS and PFS stratified by WHO tumor grade
(Figures 1A,B). Evaluation based on tumor location showed
that PFS6 was 90.5% (CI: 0.79–1.00) for skull base tumors with
83.3% (CI: 0.54–1.00) for parasagittal meningiomas while PFS6
was 50.0% (0.15–0.85) for convexity lesions (Table 3.2). Median
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TABLE 3.2 | Median progression free survival and progression free survival at 6 months, 1 year, and 3 years based on tumor location and size (n = 43).
PFS Parasagittal
(CI 95%)
Convexity
(CI 95%)
Skull Base
(CI 95%)
Mixed
(CI 95%)
Size
(< 3cm)
(CI 95%)
Size
(3-6 cm)
(CI 95%)
Size
(>6cm)
(CI 95%)
6 months 83.3% (0.54–1.00) 50.0% (0.15–0.85) 90.5% (0.79–1.00) 60% (0.17–1.00) 73% (0.54–0.92) 80% (0.63–0.98) 100
1 year 62.5% (0.20–1.00) 33.3% (0–0.68) 85.2% (0.70–1.00) – 66.4% (0.44–0.89) 68.7% (0.48–0.90) –
3 years – – 68.1% (0.36–1.00) – 44.3% (0.06–0.83) 22.9 (0–0.60) –
Median PSF 2.38 0.68 3.22 (2.96–4.53) – 3.10 (0.51–4.53) 2.38 (0.87–3.22) 1.77 (–)
(–), undetermined.
TABLE 3.3 | Median progression free survival and progression free survival based on treatment history at 6 months, 1, and 3 years (n = 43).
PFS Radiation
(CI 95%)
Non-radiation
(CI 95%)
Surgical
(CI 95%)
Non-surgical
(CI 95%)
Chemo-therapy
(CI 95%)
Non-chemotherapy
(CI 95%)
6 months 85.2% (0.70–1.00) 94.7% (0.85–1.00) 74.3% (0.59–0.90) 88.9% (0.68–1.00) 42.9% (0.06–0.80) 84.8% (0.73–0.97)
1 year 85.2% (0.70–1.00) 94.7% (0.85–1.00) 62.7% (0.45–0.80) – 14.3% (0–0.40) 81.0% (0.67–0.95)
3 years 49.7% (0.07–0.93) 82.9% (0.59–1.00) 37.4% (0.10–0.64) – – 57.6% (0.27–0.88)
Median PFS 2.97 (1.76–(–)) 2.97 (1.76–(–)) 2.37 years
(0.87–4.53)
– 0.51 (0.19–1.0) 3.10 (2.37–4.53)
(–), undetermined.
TABLE 4.1 | Median overall survival and overall survival at 6 months, 1, and 3 years (n = 43).
OS WHO Grade 1
(CI 95%)
WHO Grade 2
(CI 95%)
WHO Grade 3
(CI 95%)
ALL
(CI 95%)
6 months 96.4% (0.90–1.00) 100% 83.3% (0.54–1.00) 94.8% (0.85–1.00)
1 year 96.4% (0.90–1.00) 100% 41.7% (0.00–0.85) 88.1% (0.77–0.99)
3 years 77.1 (0.43–1.00) * * 67.0% (0.36–0.98)
Median OS – – 1.0 (0.31–(–)) –
*Final case was censored before this point, (–), undetermined.
PFS for small tumors was 3.22 years (CI: 2.96–4.53) (Table 3.2).
Analysis based on the treatment history identified that PFS6 for
patients with no history of radiation was 94.7% (CI: 0.85–1.00),
no surgeries 88.9% (CI: 0.68–1.00) and no chemotherapy was
84.8% (CI: 0.73–0.97) (Table 3.3). Patients with ER-PR+ tumors
had PFS6 of 87.8% (CI: 0.72–1.00) while patients with ER-PR-
meningiomas had PFS6 of 62.5% (CI: 0.28–0.96).
The median OS for all tumor grades has not been yet reached,
thus it could not be reported (Table 4.1). There was a low event
rate in which half of patients remained alive. The median OS
for WHO grade III meningioma was 1.0 (95% CI: 0.45–1.56).
The OS for all tumor grades at 6 months was 94.9% (95% CI:
0.88–1.00), 88.4% (95% CI: 0.78–0.99) at 1 year, and 67.2% (95%
CI: 0.36–0.99) at 3 years. The OS was also calculated for each
WHO tumor grade at 6 months, 1 and 3 years. The OS for I,
II, and III at 6 months were 96.6% (95% CI: 0.90–1.00), 100%,
and 83.3% (95% CI: 0.54–1.00) respectively. At 1 year, the OS
for WHO grade I was 96.6% (95% CI: 0.90–1.00), 100% for
WHO grade II and for WHO grade III was 62.5% (95% CI:
0.21–1.00). The OS at 3 years for WHO grade I was 77.2%
(95% CI: 0.43–1.00). Kaplan Meier curves were generated to
show OS and OS stratified by WHO grade (Figures 1C,D). The
median OS was achieved for patients with convexity tumors
(1.75 years), medium tumor size (2.97 years), and 2.97 years
for patients with no prior history of radiation or surgeries
(Tables 4.2 and 4.3).
DISCUSSION
Currently, there are no FDA approved therapies for management
of surgically inaccessible or radiation-refractory recurrent
meningiomas. In 2019, the Central Nervous System NCCN
guideline recommended somatostatin analogs as valuable
therapeutic options for management of progressive or
recurrent meningiomas (6). These recommendations were
derived from limited studies evaluating various somatostatin
analogs (somatostatin, pasireotide, octreotide, and Sandostatin
LAR). Our study, on the other hand, is one of the largest
reported retrospective analysis of meningioma patients with
recurrent and/or progressive disease treated with Sandostatin
LAR (octreotide).
Comprehensive review of our study and previously reported
data are summarized in Table 5. We utilized similar inclusions
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TABLE 4.2 | Median overall survival and overall survival at 6 months, 1 year, and 3 years based on tumor location and size (n = 43).
OS Parasagittal
(CI 95%)
Convexity
(CI 95%)
Skull Base
(CI 95%)
Mixed
(CI 95%)
Size
(< 3cm)
(CI 95%)
Size
(3-6 cm)
(CI 95%)
Size
(>6cm)
(CI 95%)
6 months 100% 87.5% (0.64–1.00) 95% (0.85–1.00) – 94.4% (0.84–1.00) 94.7% (0.85–1.00) 100%
1 year 80% (0.44–1.00) 65.6% (0.24–1.00) 95% (0.85–1.00) – – 82.1% (63.6–100) –
3 years – – 76% (0.42–1.00) – – – –
Median OS – 1.75 (–) – – – 2.97 (–)
(–), undetermined.
TABLE 4.3 | Median overall survival and overall survival based on treatment history at 6 months, 1 year, and 3 years (n = 43).
OS Radiation
(CI 95%)
Non-radiation
(CI 95%)
Surgical
(CI 95%)
Non-surgical
(CI 95%)
Chemo-therapy
(CI 95%)
Non-chemotherapy
(CI 95%)
6 months 95% (0.85–1.00) 94.7% (0.85–1.00) 96.7% (0.90–1.00) 88.9% (0.68–1.00) 100% 93.7% (0.85–1.00)
1 year 83.1% (0.66–1.00) 94.7% (0.85–1.00) 88.1% (0.75–1.00) 88.9% (0.68–1.00) 83.3% (0.54–1.00) 89.6% (0.78–1.00)
3 years 83.1% (0.66–1.00) 41.5% (0–1.00) 82.6% (0.66–0.98) 0 62.5% (0.20–1.00) 67.2% (0.28–1.00)
Median – 2.97 (1.76–(–)) – 2.97 (0.35–2.97) – –
(–), undetermined.
TABLE 5 | Studies of octreotide analogs in refractory recurrent meningiomas.
Author, year of publication Number of patients and
WHO grade of
meningioma
Median
KPS
PFS6 (%) Median TTP/PFS
(months)
Median OS
(months)
Common toxicities
Chamberlain et al.
Sandostatin LAR (16)
16
(I, n = 8; II, n = 3; III, n = 5)
80 44 5 7.5 Diarrhea
Johnson et al.
Sandostatin LAR (17)
Meningiom a:11
(I, n = 3; II, n = 3; III, n = 5)
Hemangiopericytom a: 1
ND ND 4.25 32.4 Diarrhea, anorexia, nausea,
transaminitis
Schulz et al.
Sandostatin LAR (14)
13
(I, n = 8 localized to skull
base that underwent
analysis)
ND ND 24 ND Well-tolerated, n = 1
psychiatric side effects
Simo et al.
Octreotide (22)
9
(II, n = 5; III, n = 4)
80 44.4 4.23 18.7 Diarrhea
Norden et al.
Pasireotide LAR (SOM230C) (23)
28
(I, n = 16; II/III n = 18)
85 32 4.5 Not achieved Hyperglycemia,
hypoglycemia, elevated
amylase, elevated lipase,
fatigue, hypokalemia
Graillon et al.
Everolimus and Octreotide (24)
20
(I, n = 2; II, n = 10, III n = 8)
ND 55 ND ND Stomatitis, fatigue, diarrhea
Our study 43
(I, n = 32; II, n = 5, III n = 6)
80 80 35.6 Not achieved Diarrhea, headache
and exclusions criteria as prior trials. For instance, we included
adult patients with recurrent or progressive meningioma
diagnosed by PET scan (14, 22) and/or biopsy proven as in
Johnson et al. (17). Prior radiotherapy, chemotherapy treatments
and/or surgeries were permitted, as it was done in Chamberlain
et al. and Johnson et al. (16, 17), in contrast to the study by
Simo et al. that included only chemotherapy naïve patients (22).
The results of our study were compatible and showed noted
improvement from prior investigations. Specifically, PFS6 in our
study for all tumor grades was 80.0% while prior studies reported
PFS6 in 32.0–44.4% range (14, 16, 17, 22).
The OS for all tumor grades has not been achieved in our
study, while other investigations reported OS ranged from 7.5
to 34.2 months. Median KPS status in all studies ranged from
80 to 85. The prospective pilot trial conducted by Chamberlain
et al. included 16 patients with low and high grade recurrent
meningiomas who received treatment with Sandostatin LAR
(octreotide) (16). Analysis indicated PFS6 of 44%, median TTP
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TABLE 6 | Targeted therapy for progressive recurrent meningiomas.
Author, year of
publication
Inhibitor Target N Tumor
Grade
Median
KPS
PFS6 (%) Median TTP/PFS
(months)
Common toxicities Grade 4 or 5
toxicity
Nayak et al. (28) Bevacizumab VEGF 15 II, III ND 43.7 6.5 Fatigue, cerebral hemorrhage No
Lou et al. (29) Bevacizumab VEGF 14 I, II, III 80 85.7 17.9 Thrombocytopenia, proteinuria,
craniotomy site cellulitis
Yes
Nunes et al. (30) Bevacizumab VEGF 15 NF2 ND 85 15 Hypertension, transaminitis,
menorrhagia, irregular menses
No
Alanin et al. (31) Bevacizumab VEGF 7 NF2 ND ND ND Intracerebral hemorrhage Yes
Shih et al. (32) Bevacizumab+
everolimus
VEGF
mTOR
17 I, II, III ND 69 22 Colitis, chronic thrombotic
microangiopathy, proteinuria,
nephrotic syndrome
No
Wen et al. (33) Imatinib PDGFR 23 I, II, III 80 29.4 2 Anemia, leukopenia,
neutropenia, dehydration,
dizziness, hypophosphatemia
Yes
Horak et al. (34) Imatinib PDGFR 9 I, II, III ND 66.7 17 ND ND
Reardon et al. (35) Imatinib +
hydroxyurea
PDGFR 21 I, II, III ND 61.9 7 Anemia, constipation, edema,
fatigue, hypoalbuminemia,
hypophosphatemia, rash,
neutropenia, thrombocytopenia
Yes
of 5 months and median OS of 7.5 months with minimal toxicity.
The phase II study by Johnson et al. evaluated 12 patients with
all tumor grades reported median TTP as 4.25 months and
medianOS as 32.4months (17). Schulz et al. evaluated 13 patients
with WHO tumor grade I meningiomas, and only median TTP
was reported as 24 months (14). Simo et al. conducted phase
II trial on patients with high-grade meningiomas who received
subcutaneous octreotide injections every 28 days and reported
PFS6 as 44.4%, median TTP as 4.23 months, and median OS
as 18.7 months (22). Norden et al. showed no radiographic
response to therapy with pasireotide LAR (SOM230C) on 28
patients with recurrent meningiomas of all tumor grades, PFS6
as 32% and median TTP as 4.5 months, but overall OS was not
reached (23). The prospective phase II clinical trial by Graillon
et al. evaluated the benefits of combination of everolimus and
octreotide in patients with recurrent meningioma who were
ineligible for further interventions (24). The PFS at 6 months was
55%, the overall survival rates at 6 and 12 months were 90 and
75%, respectively (24).
Only one prior study by Schulz et al. evaluated PFS
based on the tumor location. Schulz et al. evaluated eight
patients with skull based WHO grade I tumors and showed
PFS was 100% at 48 months with two patients discontinued
treatment after 36 months without disease progression (14).
Our study included 23 patients with skull-based tumor of
which 21 patients had WHO grade 1 meningiomas. The PFS6
for skull-based tumors was 90.5% which is consistent with
Schulz et al. No analysis based on tumor grade, location or
receptor type were performed in other studies that investigated
Sandostatin LAR (16, 17, 22). Our data showed no radiological
regression as defined by the RANO criteria (25) which is
in agreement with previously published data. Based on in
vitro studies showing that octreotide significantly decreased
cell proliferation but did not induce cell death (13, 14), it
is not surprising that prior prospective studies investigating
the efficacy of Sandostatin LAR on meningioma showed no
evidence of radiological tumor regression (14, 16, 17, 22,
23). It was suggested that even though no radiographical
tumor regression was detected, Sandostatin LAR may arrest
tumor progression (17). Only recent Phase II clinical trial that
evaluated the effectiveness of combination of everolimus and
octreotide showed that among the 20 study patients, radiological
regression in the tumor volume by >10% was identified in 4
patients (24).
Evaluation based on tumor size and location revealed that
the patients with skull-based and small tumors had the longest
median PFS of 3.22 and 3.1 years respectively. Interestingly,
our cohort showed no difference in the median PFS based
on the radiation status while the patients with no history of
chemotherapy were noted to have the median PFS of 3.10 years.
The patients who underwent surgeries had the median PFS of
2.37 years. Thus, patients with small skull-based tumors with
prior surgeries and no history of chemotherapy had the longest
median PFS without respect to prior history of radiation.
Evaluation of PFS6 based on the effect of estrogen and
progesterone on meningioma was performed. Analysis showed
that patients with ER-PR+ tumors had PFS6 of 87.8% (CI: 87.8%
(0.72–1.00) while patients with ER-PR- meningiomas had PFS6
of 62.5% (CI:0.28–0.96). These findings are in agreement with
previously published data noting that lack of PR expression to
be correlated with high tumor grade and tumor recurrence.
Pravdenkova et al. showed that expression of the PR alone in
meningioma signals a favorable clinical and biological outcome
while the lack of receptors correlates with aggressive clinical
behavior, progression or recurrence of this tumors (26). Recent
retrospective study showed that patients with meningioma with
ER+ had a much worse prognosis than those with ER weak or
ER- status [Hua]. Since our analysis mainly included patients
with ER+ status at least indicates that more than 58% of the
cohort had ER+ status (27).
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Reported toxicities were consistent across clinical studies with
diarrhea, abdominal pain, nausea, vomiting and transaminities
being the most common events. Prior studies had <25 patients
that resulted in low statistical power.
Our clinical study provides additional evidence to support
the rationale for a larger phase study to assess the efficacy of
Sandostatin LAR (octreotide). Compared to other therapeutics,
Sandostatin LAR (octreotide) had the longer median PFS, PFS6
and safety profile (Table 6). There were no observed CTCAE
grade 4 or grade 5 adverse events. There was only one CTCAE
grade 3 adverse event that identified the patient who was
hospitalized with pancreatitis after developing cholelithiasis.
Sandostatin LAR (octreotide) was subsequently discontinued
in this patient. Erlotinib demonstrated a favorable safety
profile compared to all the other drugs, however, median PFS
was shorter than for the patients who received Sandostatin
LAR (octreotide).
Important to note, that the CNS NCCN guideline classifies
somatostatin analog, as a level 2A category for patients
with progressive recurrent meningioma while interferon alpha,
sunitinib and bevacizumab, and everolimus combination were
given 2B category (6). Category 2A evidence is based on
lower-level evidence with uniform NCCN consensus that the
intervention is appropriate, while category 2B evidence that
is also based on lower level of evidence was only granted
experts consensus. These recommendations are not surprising,
as scientific literature review indicates that somatostatin analogs
including Sandostatin LAR (octreotide) are better tolerated
therapies with good efficacy as evidenced by longer PSF and PFS6.
Specifically, phase II clinical trial that included 36 patients
with high-grade meningioma who received sunitibin showed
efficacy of that treatment based on PFS6 of 42%, median PFS
of 5.2 months and median OS of 24.6 months (36). However,
considerable toxicity was observed with 1 grade 5, 1 grade
4 and 2 grade 3 intratumoral hemorrhages, 1 grade 4 and 1
grade 3 thrombic microangiopathy attributed to known side
effect profile of VEGF inhibitors. By comparison all studies
on somatostatin analogs including this report indicate well-
tolerability and minimal side effects with diarrhea being the most
commonly reported side effect.
The phase II clinical study evaluated efficacy of combination
of everolimus and bevacizumab in 17 patients with progressive
recurrent meningiomas (WHO tumor grade I,II and III)
showed that this regiment was well-tolerated, and produced
stable diseases in 88% of patients with median PFS as
22 months, PFS as 69% and median OS of 23.8 months
(32). No grade 5 or grade 4 toxicities were reported, but
four patients (22%) discontinued treatment due to grade 3
toxicities such as proteinurea, colitis and thrombocytopenia.
Important to note, that since the sample size was small,
additional work in indicated. In comparison, our study is one
of largest studies that included 43 patients providing more
conclusive results.
The recently published prospective phase II clinal trial
that evaluated the efficacy of combination of everolimus and
octreotide reported that stomatitis was the most common grade
3 adverse event, seen in 55% of patients, necessitating the
discontinuation of both therapeutics in 1 patient and everolimus
in another (24).
A retrospective case series evaluated treatment with interferon
alpha for patients with high grade meningiomas that showed
progression after surgery, radiotherapy, or prior systemic
chemotherapy (37). The study revealed the median PFS12 and
PFS6 of 17% without radiographical response and moderate
toxicity. Unfortunately, given that overall PFS and PFS6 were
below benchmark criteria of PFS of 26% for atypical and
malignant meningiomas proposed by the Response Assessment
in Neuro-Oncology (RANO) Working Group 2014, it appears
to be an unlikely candidate for use for treatment of progressive
recurrent meningiomas (38).
Thus, based on available clinical data, Sandostatin LAR
(octreotide) should be given consideration for managing patients
with progressive and/or recurrent meningiomas. Nevertheless,
this was a retrospective study with several limitations, imposed
by the type of the study. Comparison of Sandostatin LAR
(octreotide) to other therapeutics were hindered, as all the
studies have different methodologies, size, patient population, or
objectives. In addition, our study did not include a control, and
prior reported studies were used for comparison. Furthermore,
numerous patients were evaluated years after the initial diagnosis
with limited number of patients who were diagnosed based on
immunohistochemistry results, hindering further stratification
based on molecular profile. Despite the stated limitations, our
study is one of the largest retrospective studies that provides
rationale and supports further investigation of Sandostatin
LAR (octreotide) for the treatment of progressive or recurrent
meningiomas. Additional prospective, larger scale randomized
trials are needed to validate the effectiveness of Sandostatin LAR
(octreotide) in meningioma.
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